tiprankstipranks
Advertisement
Advertisement

iSpecimen Completes 1-for-40 Reverse Stock Split

Story Highlights
  • iSpecimen executed a 1-for-40 reverse stock split in April 2026, sharply reducing outstanding shares and adjusting all equity-linked securities.
  • The company’s board and shareholders backed the split to boost the share price, support Nasdaq listing compliance, and validate earlier capital structure changes.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
iSpecimen Completes 1-for-40 Reverse Stock Split

Claim 55% Off TipRanks

The latest announcement is out from iSpecimen ( (ISPC) ).

iSpecimen Inc. implemented a 1‑for‑40 reverse stock split of its common stock, effective April 27, 2026, with trading on a split-adjusted basis beginning April 28, 2026, on the Nasdaq Capital Market under the symbol ISPC. The move reduced the company’s outstanding shares from 52,639,796 to approximately 1,316,032, with fractional shares rounded up, and triggered proportional adjustments to options, warrants, restricted stock units and shares reserved under equity incentive plans.

The reverse split, approved by shareholders on October 30, 2025, and finalized by the board on April 9, 2026, is aimed at lifting iSpecimen’s per‑share trading price to attract institutional investors and regain compliance with Nasdaq’s minimum bid price rules. Concurrently, on April 29, 2026, the company filed a Fifth Amended and Restated Certificate of Incorporation in Delaware, which both effected the split and validated a prior 1‑for‑20 reverse split from September 13, 2024, integrating all changes into its charter while its transfer agent manages the share exchange process for holders.

Spark’s Take on ISPC Stock

According to Spark, TipRanks’ AI Analyst, ISPC is a Neutral.

The score is weighed down primarily by very weak financial performance (sharp revenue contraction, margin collapse, large losses, and ongoing cash burn). Technicals add downside pressure with a clear downtrend and negative momentum indicators. Valuation provides limited support because the negative P/E reflects unprofitability and there is no dividend yield data.

To see Spark’s full report on ISPC stock, click here.

More about iSpecimen

iSpecimen Inc., based in Woburn, Mass., operates an online global marketplace for human biospecimens, linking scientists in commercial and non-profit research organizations with a federated network of hospitals, laboratories, biobanks, blood centers and other healthcare providers. Its proprietary cloud-based platform enables intuitive searching for patient samples needed to support medical discovery and research programs.

Average Trading Volume: 752,812

Technical Sentiment Signal: Strong Sell

Current Market Cap: $6.88M

For a thorough assessment of ISPC stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1